Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

For many years, survival rates for advanced bladder cancer have remained stagnant, but our findings offer hope to thousands of patients who face this devastating diagnosis. 'Patients treated with ...

A phase 3 clinical trial has shown that patients were 32 per cent less likely to experience cancer recurrence when treated ...

Bladder cancer presents through various symptoms, ranging from subtle changes to more noticeable signs. While some symptoms ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Patients with suspected new bladder cancer were randomly assigned 1:1 to transurethral resection of bladder tumor or ...

A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the ...

This is a major breakthrough in the treatment of bladder cancer. For many years, survival rates for advanced bladder cancer have remained stagnant, but our findings offer hope to thousands of ...